REG - Venture Life Group - AGM Statement

Venture LifeAnnouncement

04/06/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240604:nRSD9394Qa&default-theme=true

RNS Number : 9394Q  Venture Life Group PLC  04 June 2024

4(th) June 2024

 

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Company")

 

AGM Statement

 

Venture Life (AIM: VLG), a leader in developing, manufacturing and
commercialising products for the self-care market, will hold its Annual
General Meeting ("AGM") at 10:00am this morning. At the meeting, the Group's
Chair, Paul McGreevy will make the following statement:

 

"On behalf of the Board, I would once again like to take this opportunity to
thank Venture Life's employees for their ongoing commitment and support. The
business continues to perform well and our increased focus on promoting the
VLG owned brands is delivering pleasing results, with an additional 35 new
listings secured within UK retail since the beginning of the year. We remain
confident about the outlook for the year ahead and our ability to deliver full
year performance in line with management's expectations. Further commentary
over first half trading will be provided as part of our usual business update
in July."

 

Resolution 10 has been withdrawn prior to the commencement of the AGM as
certain of the Company's shareholders had indicated that they would not be
supportive of the resolution. Resolution 10 was the proposed disapplication of
pre-emption rights in order for the Board to allot equity securities of up to
an aggregate nominal amount of £37,949.46. The Board had proposed Resolution
10 as it considered the flexibility afforded by this authority to be in the
best interests of the Company and will consider further engagement with the
opposing shareholders on this matter in the future.

 

For further information, please contact:

Venture Life Group PLC
 
                +44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

 

Cavendish Capital Markets Limited (Nomad and
Broker)                                +44 (0)
20 7720 0500

Stephen Keys / Camilla Hume (Corporate Finance)

Michael Johnson (Sales)

 

About Venture Life (www.venture-life.com (http://www.venture-life.com/) )

Venture Life is an international consumer self-care company focused on
developing, manufacturing and commercialising products for the global
self-care market. With operations in the UK, Italy, and Sweden, the Group's
product portfolio includes some key products such as the Balance Active range
in the area of women's intimate healthcare, the Earol® product line in ENT
care, the Lift and Glucogel product ranges for energy and glucose management
and hypoglycaemia, the UltraDEX and Dentyl oral care product ranges, products
for fungal infections and proctology, and dermo-cosmetics for addressing the
signs of ageing. Its products are sold in over 90 countries worldwide.

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through pharmacies and grocery
multiples. In the UK and The Netherlands these are supplied direct by the
company to retailers, elsewhere they are supplied by the Group's international
distribution partners.

Through its two Development & Manufacturing operations in Italy and
Sweden, the Group also provides development and manufacturing services to
companies in the medical devices and cosmetic sectors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMUORBRSWUNRAR